Daunorubicin HCl
别名: Rubidomycin HCl, RP 13057 HCl 中文名称：道诺霉素,盐酸柔红霉素, 盐酸正丁霉素
Daunorubicin HCl抑制DNA和RNA合成，无细胞试验中抑制DNA合成的Ki为0.02 μM。Daunorubicin 是 topoisomerase II 的抑制剂并可诱导凋亡。
Daunorubicin HCl Chemical Structure
CAS: 23541-50-6
产品质控
批次：
纯度：
99.98%
99.98
Daunorubicin HCl相关产品
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| KB | Apoptosis assay | 1 uM | 24 hrs | Induction of apoptotic activity in human KB cells at 1 uM after 24 hrs | 18680275 |
| DU145 | Function assay | 90 nM | 72 hrs | Inhibition of topoisomerase 2 in human DU145 cells assessed as stabilization of enzyme-DNA cleavage complex at 90 nM after 72 hrs by immunoblot analysis | 22260166 |
| DU145 | Function assay | 90 nM | 30 mins | Inhibition of topoisomerase 2 in human DU145 cells assessed as stabilization of enzyme-DNA cleavage complex at 90 nM after 30 mins by immunoblot analysis | 22260166 |
| DU145 | Function assay | 500 nM | 4 hrs | Inhibition of HDAC6-mediated tubulin acetylation in human DU145 cells at 500 nM after 4 hrs by Western blot analysis | 22260166 |
| DU145 | Function assay | 0.1 to 0.5 uM | 24 hrs | Inhibition of HDAC in human DU145 cells assessed as histone H3 hyperacetylation at 0.1 to 0.5 uM after 24 hrs by Western blot analysis | 22260166 |
| DA-3 | Cytotoxicity assay | 20 uM | 60 mins | Cytotoxicity against mouse DA-3 cells assessed as reduction in cell viability at 20 uM after 60 mins by XTT assay | 24900668 |
| P388 | Antitumor assay | 0.25 to 10 mg/kg | Antitumor activity against mouse P388 cells allografted in mouse assessed as tumor growth inhibition at 0.25 to 10 mg/kg | 1255661 | |
| L1210 | Function assay | 3 hrs | Inhibition of RNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-uridine addition measured after 1 hr by scintillation spectrometric analysis, ED50 = 0.3 μM. | 176359 | |
| L1210 | Function assay | 3 hrs | Inhibition of DNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-thymidine addition measured after 1 hr by scintillation spectrometric analysis, ED50 = 0.3 μM. | 176359 | |
| PC-3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human PC-3 cells after 48 hrs by MTT assay, IC50 = 0.44 μM. | 17190447 | |
| HeLa | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HeLa cells after 48 hrs by MTT assay, IC50 = 0.32 μM. | 17190447 | |
| MDA-MB-231 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 0.25 μM. | 17190447 | |
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay, IC50 = 0.22 μM. | 17190447 | |
| MDA-MB-231 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay, GI50 = 0.02 μM. | 19968258 | |
| HT-29 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HT-29 cells after 72 hrs by sulforhodamine B assay, GI50 = 0.07 μM. | 19968258 | |
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay, GI50 = 0.08 μM. | 19968258 | |
| K562 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human K562 cells after 72 hrs by XTT assay, GI50 = 0.0074 μM. | 20591678 | |
| NCI-H460 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NCI-H460 cells after 72 hrs by XTT assay, GI50 = 0.38 μM. | 20591678 | |
| SF268 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SF268 cells after 72 hrs by XTT assay, GI50 = 0.6 μM. | 20591678 | |
| MCF7 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MCF7 cells after 72 hrs by XTT assay, GI50 = 0.86 μM. | 20591678 | |
| Detroit 551 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human Detroit 551 cells after 72 hrs by XTT assay, GI50 = 1.77 μM. | 20591678 | |
| HL60 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by trypan blue staining-based hemocytometric analysis, GI50 = 0.1 μM. | 25874335 | |
| HL60R | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HL60R cells expressing p-glycoprotein assessed as growth inhibition after 48 hrs by trypan blue staining-based hemocytometric analysis, GI50 = 38 μM. | 25874335 | |
| P388 | Antiproliferative assay | 48 hrs | Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay, IC50 = 0.028 μM. | 2778449 | |
| HT-29 | Antiproliferative assay | 96 hrs | Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay, IC50 = 0.133 μM. | 2778449 | |
| A2780 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A2780 cells after 72 hrs by MTT assay, IC50 = 0.11749 μM. | 17890094 | |
| A2780/ADR | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A2780/ADR cells after 72 hrs by MTT assay, IC50 = 18.6209 μM. | 17890094 | |
| NIH/3T3 | Cytotoxicity assay | 72 hrs | Intrinsic cytotoxicity against wild type mouse NIH/3T3 cells after 72 hrs by MTT assay, IC50 = 0.044 μM. | 18954040 | |
| NIH/3T3 | Cytotoxicity assay | 72 hrs | Intrinsic cytotoxicity against mouse NIH/3T3 cells overexpressing MDR1 after 72 hrs by MTT assay, IC50 = 1.01 μM. | 18954040 | |
| KB | Cytotoxicity assay | 48 hrs | Cytotoxicity against human KB cells after 48 hrs by MTT assay, IC50 = 0.64 μM. | 20363142 | |
| KB-C2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human multidrug-resistant KB-C2 cells after 48 hrs by MTT assay, IC50 = 16.2 μM. | 20363142 | |
| HT-29 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HT-29 cells after 24 hrs by MTS assay, IC50 = 0.4 μM. | 21094049 | |
| HepG2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay, IC50 = 0.7 μM. | 21094049 | |
| NIH/3T3 | Cytotoxicity assay | 3 days | Cytotoxicity against mouse NIH/3T3 cells after 3 days by MTS assay, IC50 = 1.8 μM. | 21094049 | |
| Vero | Cytotoxicity assay | 3 days | Cytotoxicity against african green monkey Vero cells after 3 days by MTS assay, IC50 = 2.5 μM. | 21094049 | |
| MCF7 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human MCF7 cells after 24 hrs by MTS assay, IC50 = 5.5 μM. | 21094049 | |
| CRL7761 | Cytotoxicity assay | 3 days | Cytotoxicity against human CRL7761 cells after 3 days by MTS assay, IC50 = 10.5 μM. | 21094049 | |
| DU145 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human DU145 cells after 72 hrs by MTS assay, IC50 = 0.09 μM. | 22260166 | |
| SKMES1 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SKMES1 cells after 72 hrs by MTS assay, IC50 = 0.17 μM. | 22260166 | |
| MCF7 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay, IC50 = 0.95 μM. | 22260166 | |
| LNCAP | Cytostatic assay | 4 days | Cytostatic activity against human LNCAP cells after 4 days by MTT assay, IC50 = 0.1 μM. | 22480495 | |
| HT-29 | Cytostatic assay | 4 days | Cytostatic activity against human HT-29 cells after 4 days by MTT assay, IC50 = 0.2 μM. | 22480495 | |
| MCF7 | Cytostatic assay | 4 days | Cytostatic activity against human MCF7 cells after 4 days by MTT assay, IC50 = 0.4 μM. | 22480495 | |
| THP1 | Cytotoxicity assay | 72 hrs | Cytotoxicity against PMA-stimulated human THP1 cells after 72 hrs by MTT assay, IC50 = 26.9 μM. | 22939695 | |
| L5178Y | Cytotoxicity assay | 24 hrs | Cytotoxicity against mouse L5178Y cells after 24 hrs by MTT assay, IC50 = 0.3 μM. | 23199479 | |
| L5178Y | Cytotoxicity assay | 24 hrs | Cytotoxicity against mouse L5178Y cells after 24 hrs by MTT assay, IC50 = 0.73 μM. | 23199479 | |
| L5178Y | Cytotoxicity assay | 24 hrs | Cytotoxicity against mouse L5178Y cells expressing p-gp after 24 hrs by MTT assay, IC50 = 2.32 μM. | 23199479 | |
| L5178Y | Cytotoxicity assay | 24 hrs | Cytotoxicity against mouse L5178Y cells expressing p-gp after 24 hrs by MTT assay, IC50 = 7.73 μM. | 23199479 | |
| DA-3 | Cytotoxicity assay | 24 hrs | Cytotoxicity against mouse DA-3 cells after 24 hrs by XTT assay, IC50 = 1.9 μM. | 24900668 | |
| SKOV3 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human SKOV3 cells after 24 hrs by XTT assay, IC50 = 20.6 μM. | 24900668 | |
| ES2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human ES2 cells after 24 hrs by XTT assay, IC50 = 25.5 μM. | 24900668 | |
| MCF7 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay, IC50 = 33.9 μM. | 24900668 | |
| HEK293 | Cytotoxicity assay | 24 hrs | Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by Alamar Blue assay, IC50 = 12.55 μM. | 26937828 | |
| MCF7/ADR | Growth inhibition assay | 48 hrs | Growth inhibition of human MCF7/ADR cells after 48 hrs by SRB assay, IC50 = 7.12 μM. | 28246041 | |
| HCT16 | Cytotoxicity assay | 72 hrs | Cytotoxicity in human HCT16 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay, IC50 = 0.21 μM. | 28923382 | |
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay, IC50 = 0.51 μM. | 28923382 | |
| MCF7 | Cytotoxicity assay | 72 hrs | Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay, IC50 = 1.44 μM. | 28923382 | |
| RD | Cytotoxicity assay | 72 hrs | Cytotoxicity in human RD cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay, IC50 = 2.45 μM. | 28923382 | |
| HEK293 | Cytotoxicity assay | 72 hrs | Cytotoxicity in human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay, IC50 = 11.17 μM. | 28923382 | |
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay, LC50 = 0.35 μM. | 19968258 | |
| MDA-MB-231 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay, LC50 = 0.86 μM. | 19968258 | |
| CEM | Cytotoxicity assay | 72 hrs | Cytotoxicity against CEM cells after 72 hrs, TCS50 = 0.062 μM. | 17608396 | |
| MCF7 | Cytotoxicity assay | 72 hrs | Cytotoxicity against MCF7 cells after 72 hrs, TCS50 = 0.14 μM. | 17608396 | |
| K562 | Cytotoxicity assay | 72 hrs | Cytotoxicity against K562 cells after 72 hrs, TCS50 = 0.23 μM. | 17608396 | |
| HOS | Cytotoxicity assay | 72 hrs | Cytotoxicity against HOS cells after 72 hrs, TCS50 = 0.33 μM. | 17608396 | |
| G361 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human G361 cells after 72 hrs, TCS50 = 0.67 μM. | 17608396 | |
| HeLa | Cytotoxicity assay | 72 hrs | Cytotoxicity against HeLa cells after 72 hrs, TCS50 = 0.67 μM. | 17608396 | |
| MDA-MB-231 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay, TGI = 0.12 μM. | 19968258 | |
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay, TGI = 0.17 μM. | 19968258 | |
| HT-29 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HT-29 cells after 72 hrs by sulforhodamine B assay, TGI = 0.33 μM. | 19968258 | |
| L1210 | Function assay | Inhibition of DNA synthesis in mouse L1210 cells, ED50 = 0.66 μM. | 490536 | ||
| L1210 | Function assay | Inhibition of RNA synthesis in mouse L1210 cells, ED50 = 0.33 μM. | 490536 | ||
| L1210 | Function assay | Inhibition of DNA synthesis in mouse L1210 cells, ED50 = 0.66 μM. | 423182 | ||
| L1210 | Function assay | Inhibition of RNA synthesis in mouse L1210 cells, ED50 = 0.33 μM. | 423182 | ||
| fibroblast (NHF) cells | Cytotoxicity assay | Cytotoxicity that caused a 50% reduction in absorbance at 490 nm in normal human fibroblast (NHF) cells using MTS assay, EC50 = 0.22 μM. | 11020285 | ||
| B16 | Cytotoxicity assay | Cytotoxicity that caused a 50% reduction in absorbance at 490 nm in B16 mouse melanoma cells using MTS assay, EC50 = 0.16 μM. | 11020285 | ||
| HTB-81 | Cytotoxicity assay | Cytotoxicity that caused a 50% reduction in absorbance at 490 nm in human prostate cancer HTB-81 cells using MTS assay, EC50 = 0.058 μM. | 11020285 | ||
| HL60 | Apoptosis assay | Induction of apoptosis in multidrug resistant human HL60 cells after 48 hrs, AC50 = 38 μM. | 18339455 | ||
| HL60 | Cytotoxicity assay | Cytotoxicity against human HL60 cells after 48 hrs by trypan blue exclusion method, AC50 = 0.1 μM. | 18339455 | ||
| HL60R | Apoptosis assay | In vitro concentration required to induce apoptosis in HL60R cells, AC50 = 10 μM. | 12877593 | ||
| HL60 | Apoptosis assay | In vitro concentration required to induce apoptosis in HL60 cells, AC50 = 0.04 μM. | 12877593 | ||
| Yoshida sarcoma tumor cells | Function assay | Concentration inhibiting [3H]TdR incorporation in Yoshida sarcoma tumor cells in vitro in rats, IC50 = 0.02 μM. | 1322986 | ||
| L1210 | Function assay | Dose required to inhibit the DNA synthesis in leukemia L1210 cells, ED50 = 1 μM. | 7252976 | ||
| L1210 | Function assay | Dose required to inhibit the RNA synthesis in leukemia L1210 cells, ED50 = 0.3 μM. | 7252976 | ||
| L1210 | Function assay | Inhibition of [3H]thymidine incorporation into proliferating L1210 cells, ED50 = 0.66 μM. | 6716401 | ||
| L1210 | Function assay | Inhibition of [3H]uridine incorporation into proliferating L1210 cells, ED50 = 0.33 μM. | 6716401 | ||
| L1210 | Function assay | Inhibition of DNA synthesis in mouse L1210 cells assessed as inhibition of [3H]thymidine incorporation, ED50 = 0.4 μM. | 490537 | ||
| L1210 | Function assay | Inhibition of RNA synthesis in mouse L1210 cells assessed as inhibition of [3H]uridine incorporation, ED50 = 0.3 μM. | 490537 | ||
| L1210 | Function assay | Inhibition of DNA synthesis in mouse L1210 cells, ED50 = 1 μM. | 423181 | ||
| L1210 | Function assay | Inhibition of RNA synthesis in mouse L1210 cells, ED50 = 0.3 μM. | 423181 | ||
| NCI-H69 cell line | Proliferation assay | Antiproliferative activity against drug sensitive NCI-H69 cell line by Alamar Blue assay, IC50=0.1 μM | 17286393 | ||
| human HeLa3 cell line | Cytotoxic assay | Cytotoxicity against human HeLa3 cell line by MTT assay, IC50=2.96 μM | 16942037 | ||
| Jurkat T lymphocytes | Cytotoxic assay | Cytotoxicity against Jurkat T lymphocytes by MTT assay, IC50=0.0826 μM | 16366602 | ||
| human uterine sarcoma cell line MES-SA | Cytotoxic assay | In vitro cytotoxic activity was evaluated using the human uterine sarcoma cell line MES-SA, IC50=0.07 μM | 12443763 | ||
| human epidermoid carcinoma cell line KB-3-1 | Cytotoxic assay | In vitro cytotoxic activity was evaluated using the human epidermoid carcinoma cell line KB-3-1, IC50=7 nM | 12443763 | ||
| Dx5 cell lines | Growth inhibition assay | The compound was evaluated for the growth inhibition of Dx5 cell lines using MTT assay, ic50=2 μM | 10698449 | ||
| MES-SA uterine tumor cell lines | Growth inhibition assay | The compound was evaluated for the growth inhibition of MES-SA uterine tumor cell lines using MTT assay, IC50=0.021 μM | 10698449 | ||
| Dx5 w/PSC cell lines | Growth inhibition assay | The compound was evaluated for the growth inhibition of Dx5 w/PSC cell lines using MTT assay, IC50=14 nM | 10698449 | ||
| P388 leukemia cell line | Cytotoxic assay | Compound was evaluated for cytotoxicity against P388 leukemia cell line, IC50=3 nM | 10479297 | ||
| MDA MB 361(mammary carcinoma cell line) | Cytotoxic assay | The compound was tested for intracellular cytotoxicity against MDA MB 361(mammary carcinoma cell line) expressing LacZ (beta-galactosidase), IC50=17 nM | 10395490 | ||
| L1210 | Function assay | Inhibition of RNA synthesis in mouse L1210 cells, ED50 = 0.23 μM. | 690999 | ||
| L1210 | Function assay | Inhibition of DNA synthesis in mouse L1210 cells, ED50 = 0.48 μM. | 690999 | ||
| L1210 | Function assay | Compound was evaluated for the 50% inhibition of the incorporation of [3H]- thymidine in the RNA (inhibition of synthesis in leukemia L1210 cells), ED50 = 0.33 μM. | 3761325 | ||
| L1210 | Function assay | Compound was evaluated for the 50% inhibition of the incorporation of [3H]- thymidine in the DNA (inhibition of synthesis in leukemia L1210 cells), ED50 = 0.66 μM. | 3761325 | ||
| L1210 | Function assay | Concentration of drug necessary to reduce by 50% the incorporation of tritiated uridine in the RNA of actively growing L1210 cells, ED50 = 0.33 μM. | 7086816 | ||
| L1210 | Function assay | Concentration of drug necessary to reduce by 50% the incorporation of tritiated thymidine in the DNA of actively growing L1210 cells, ED50 = 0.66 μM. | 7086816 | ||
| NCI60 | Growth inhibition assay | Growth inhibition of human NCI60 cells, GI50 = 0.044 μM. | 19944612 | ||
| HeLa | Function assay | TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.05 uM) in membrane vesicle from MRP1-expressing HeLa cells, IC50 = 8 μM. | 8621644 | ||
| breast carcinoma line cells | Function assay | compound was tested in vitro for inhibition activity against a sensitive human breast carcinoma line cells, IC50 = 0.06 μM. | 9258351 | ||
| breast carcinoma line cells | Function assay | compound was tested in vitro for inhibition activity against doxorubicin resistant counterpart of human breast carcinoma line cells, IC50 = 2 μM. | 9258351 | ||
| MCF-7 | Function assay | Compound was tested for its toxicity against human breast cancer cells(MCF-7), IC50 = 0.06 μM. | 9548820 | ||
| MCF-7/ADR | Function assay | Compound was tested for its toxicity against doxorubicin resistant human breast cancer cells (MCF-7/ADR), IC50 = 2 μM. | 9548820 | ||
| L1210 | Function assay | Inhibitory activity was measured against murine L1210 leukemia cells, IC50 = 0.03 μM. | 9733483 | ||
| HL60 | Function assay | In vitro inhibitory concentration against proliferation of HL60 cells, IC50 = 0.005 μM. | 12877593 | ||
| HL60R | Function assay | In vitro inhibitory concentration against proliferation of HL60R cells along with 5 (uM) verapamil, IC50 = 0.04 μM. | 12877593 | ||
| HL60R | Function assay | In vitro inhibitory concentration against proliferation of HL60R cells, IC50 = 1.5 μM. | 12877593 | ||
| K562 | Cytotoxicity assay | Cytotoxicity against K562 cells by MTS, IC50 = 0.015 μM. | 16451059 | ||
| P388 | Antiproliferative assay | Antiproliferative activity against P388 cells by ELISA, IC50 = 0.025 μM. | 17154505 | ||
| P388 | Antiproliferative assay | Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM verapamil by ELISA, IC50 = 0.04 μM. | 17154505 | ||
| MDA435/LCC6 | Antiproliferative assay | Antiproliferative activity against MDA435/LCC6 cells by ELISA, IC50 = 0.079 μM. | 17154505 | ||
| P388 | Antiproliferative assay | Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA, IC50 = 0.106 μM. | 17154505 | ||
| MDA435/LCC6 | Antiproliferative assay | Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA, IC50 = 0.129 μM. | 17154505 | ||
| MDA435/LCC6 | Antiproliferative assay | Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA, IC50 = 0.977 μM. | 17154505 | ||
| P388 | Antiproliferative assay | Antiproliferative activity against adriamycin resistant P388 cells by ELISA, IC50 = 2.111 μM. | 17154505 | ||
| NCI-H460 | Anticancer assay | Anticancer activity against human NCI-H460 cells, IC50 = 0.38 μM. | 21599000 | ||
| SF268 | Anticancer assay | Anticancer activity against human SF268 cells, IC50 = 0.6 μM. | 21599000 | ||
| MRC5 | Antiproliferative assay | Antiproliferative activity against human MRC5 cells, IC50 = 0.88 μM. | 21599000 | ||
| MCF7 | Anticancer assay | Anticancer activity against human MCF7 cells, IC50 = 5.03 μM. | 21599000 | ||
| HepG2 | Function assay | HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells, IC50 = 2.99 μM. | 22586124 | ||
| MRC5 | Antiproliferative assay | Antiproliferative activity against human MRC5 cells by XTT assay, IC50 = 0.078 μM. | 25467291 | ||
| A549 | Antiproliferative assay | Antiproliferative activity against human A549 cells by XTT assay, IC50 = 0.08 μM. | 25467291 | ||
| MDA-MB-231 | Antiproliferative assay | Antiproliferative activity against human MDA-MB-231 cells by XTT assay, IC50 = 0.091 μM. | 25467291 | ||
| H1299 | Antiproliferative assay | Antiproliferative activity against human H1299 cells by XTT assay, IC50 = 0.096 μM. | 25467291 | ||
| MCF7 | Antiproliferative assay | Antiproliferative activity against human MCF7 cells by XTT assay, IC50 = 0.65 μM. | 25467291 | ||
| CCRF-CEM | Growth inhibition assay | In vitro growth inhibitory activity against CCRF-CEM (human lymphoblastic leukemic) cells, ID50 = 0.04 μM. | 6951049 | ||
| CCRF-CEM | Function assay | Inhibitory activity against CCRF-CEM(human leukemic lymphoblastic) cells in culture, ID50 = 0.04 μM. | 7057426 | ||
| Sf9 | Function assay | TP_TRANSPORTER: ATP hydrolysis in membrane vesicle from BCRP-expressing Sf9 cells, Kact = 2.5 μM. | 11437380 | ||
| GLC4/ADR | Function assay | TP_TRANSPORTER: inhibition of DNP-SG uptake in membrane vesicles from GLC4/ADR cells, Ki = 0.95 μM. | 9188796 | ||
| SR3A | Function assay | TP_TRANSPORTER: inhibition of LTC4 uptake in membrane vesicles from SR3A cells, Ki = 0.07 μM. | 9647783 | ||
| Caco-2 | Function assay | TP_TRANSPORTER: inhibition of Taxol transepithelial transport (basal to apical) in Caco-2 cells, Ki = 2.5 μM. | 11405287 | ||
| MDCK | Function assay | TP_TRANSPORTER: inhibition of Vinblastine transepithelial transport (basal to apical) in MRP2-expressing MDCK cells, Ki = 49.4 μM. | 12134946 | ||
| GLC4/ADR | Function assay | TP_TRANSPORTER: efflux in GLC4/ADR cells, Km = 1.4 μM. | 7945406 | ||
| BTI-TN5B1-4 | Function assay | TP_TRANSPORTER: ATP hydrolysis in membrane fraction from High Five (BTI-TN5B1-4) cells, Km = 1.74 μM. | 11785684 | ||
| K562 | Function assay | Increase in the level of drug uptake in Dox-resistant K562 cells in presence of cyclosporine over its absence | 16451059 | ||
| K562 | Function assay | Increase in the level of drug efflux in Dox-resistant K562 cells in presence of cyclosporine over its absence | 16451059 | ||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 29435139 | ||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | ||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 29435139 | ||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | ||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | ||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | ||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | ||
| fibroblast cells | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 29435139 | ||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | Daunorubicin HCl抑制DNA和RNA合成，无细胞试验中抑制DNA合成的Ki为0.02 μM。Daunorubicin 是 topoisomerase II 的抑制剂并可诱导凋亡。 | ||
|---|---|---|---|
| 靶点 |
|
| 体外研究(In Vitro) | ||||
| 体外研究活性 | Daunorubicin给药后达到峰值血药浓度时的药物浓度表明，药物作用的主要机制可能是与拓扑异构酶II相互作用，至少在白血病细胞和胸腺细胞中，这可能是导致细胞凋亡的信号通路激发了生长阻滞和/或细胞杀伤。在氧化还原酶，包括细胞色素P450还原酶，NADH脱氢酶，和黄嘌呤氧化酶介导的反应中，醌结构允许daunorubicin以电子受体发挥作用。Daunorubicin浓度超过大约2–4 μM时，自由基介导的毒性和DNA交联可能变得明显。Daunorubicin在0.2 到2 μM浓度范围内抑制HeLa 细胞中DNA 和RNA合成。Daunorubicin在超过4 μM浓度范围时抑制埃利希腹水瘤细胞中DNA合成。HL-60或U-937人白血病细胞中，Daunorubic在0.5和1 μM浓度下引起细胞凋亡。[1] 在P388和U937细胞中，通过激活神经酰胺合酶从头合成，Daunorubicin刺激神经酰胺增加和细胞凋亡。[2] 人脐静脉内皮细胞中，Daunorubicin剂量依赖性增加磷脂酰丝氨酸的暴露和随后促凝血酶的活性。Daunorubicin (0.2 mM)显著增强内皮微粒的释放，其在人脐静脉内皮细胞中具有高的促凝血作用。[3] |
|||
|---|---|---|---|---|
| 实验图片 | 检测方法 | 检测指标 | 实验图片 | PMID |
| Western blot | p-Chk1 / Chk1 / p-ATR / ATR |
|
26727128 | |
| Immunofluorescence | p-Chk1 |
|
26727128 | |
| Growth inhibition assay | Cell viability |
|
30745844 | |
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04562792 | Completed | Relapsed Pediatric ALL|Relapsed Pediatric AML|Refractory Acute Myeloid Leukemia|Refractory Acute Lymphoblastic Leukemia |
Children''s Mercy Hospital Kansas City |
May 8 2020 | Phase 2 |
| NCT03878927 | Terminated | Acute Myeloid Leukemia |
Weill Medical College of Cornell University|Jazz Pharmaceuticals|Pfizer |
August 23 2019 | Phase 1 |
| NCT03896269 | Recruiting | Blasts 10-19 Percent of Bone Marrow Nucleated Cells|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|High Risk Chronic Myelomonocytic Leukemia|Recurrent Chronic Myelomonocytic Leukemia|Recurrent High Risk Myelodysplastic Syndrome|Refractory Chronic Myelomonocytic Leukemia|Refractory High Risk Myelodysplastic Syndrome |
M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
May 14 2019 | Phase 1 |
化学信息&溶解度
| 分子量 | 563.98 | 分子式 | C27H29NO10 . HCl |
| CAS号 | 23541-50-6 | SDF | Download Daunorubicin HCl SDF |
| Smiles | CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O.Cl | ||
| 储存条件(自收到货起) | |||
|
体外溶解度 |
DMSO : 100 mg/mL ( (177.31 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Water : 100 mg/mL (177.31 mM) Ethanol : Insoluble |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
Tags: buy Daunorubicin HCl | Daunorubicin HCl supplier | purchase Daunorubicin HCl | Daunorubicin HCl cost | Daunorubicin HCl manufacturer | order Daunorubicin HCl | Daunorubicin HCl distributor
